Analyst Reco. Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
67.9 ^USD	+3.32%		-1.81%	-14.69%

Apr. 02	Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	MT
Apr. 01	Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	Apr. 02	MT
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating	Mar. 28	MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating	Mar. 26	MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating	Mar. 26	MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating	Mar. 26	MT
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108	Mar. 19	MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating	Feb. 26	MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating	Feb. 21	MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept	Feb. 21	MT
Mizuho Raises PT on Axsome Therapeutics to $112 From $90 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	Feb. 15	MT
UBS Initiates Axsome Therapeutics With Buy Rating, $111 Price Target	Feb. 06	MT
RBC Initiates Axsome Therapeutics at Outperform With $126 Price Target, Cites Auvelity Launch, Stable Cash Flows From Sunosi, 'Underappreciated Pipeline Optionality'	Jan. 25	MT
Piper Sandler Raises Price Target on Axsome Therapeutics to $113 From $90, Maintains Overweight Rating	Jan. 16	MT
Citigroup Initiates Axsome Therapeutics With Buy Rating, Price Target is $125	Dec. 13	MT
Mizuho Reduces Price Target on Axsome Therapeutics to $90 From $100, Reflecting Changes in the Model, Keeps Buy Rating	Nov. 10	MT
Mizuho Increases Price Target on Axsome Therapeutics to $100 From $95, Maintains Buy Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Axsome Therapeutics to $180 From $190, Keeps Buy Rating	23-08-08	MT
BofA Securities Upgrades Axsome Therapeutics to Neutral From Underperform, Adjusts Price Target to $81 From $59	23-08-08	MT
Piper Sandler Upgrades Axsome Therapeutics to Overweight From Neutral, Adjusts Price Target to $90 From $70	23-08-08	MT
HC Wainwright Adjusts Axsome Therapeutics Price Target to $190 From $200, Maintains Buy Rating	23-07-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Analyst Reco.

Filters